Literature DB >> 30805286

Predictive Factors and Rates of Fusion in Minimally Invasive Transforaminal Lumbar Interbody Fusion Utilizing rhBMP-2 or Mesenchymal Stem Cells.

Samuel C Overley1, Steven J McAnany2, Muhammad A Anwar1, Robert K Merrill1, Andrew Lovy1, Javier Z Guzman1, Sergey Zhadanov1, Amish Doshi1, Edward Rothenberg1, Avani Vaishnav2, Catherine Gang2, Sheeraz A Qureshi2.   

Abstract

BACKGROUND: Several fusion adjuncts exist to enhance fusion rates during minimally invasive transforaminal lumbar interbody fusion (MI-TLIF). The objective of this study was to compare fusion rates in patients undergoing MI-TLIF with either rhBMP-2 or cellularized bone matrix (CBM).
METHODS: We conducted a single surgeon retrospective cohort study of patients who underwent MI-TLIF with either rhBMP-2 or CBM placed in an interbody cage. Single and multilevel procedures were included. Fusion was assessed on computed tomography scans at 12-month follow-up by an independent, blinded, board-certified neuroradiologist. Fusion rates and rate of revision surgery were compared with a Fisher exact test between the 2 groups. A multivariate regression analysis was performed to identify patient factors that were predictive of radiographic nonunion after MI-TLIF.
RESULTS: A total of 93 fusion levels in 78 patients were reviewed. Thirty-nine patients received CBM, and 39 patients received rhBMP-2. The patients receiving rhBMP-2 were older on average (61.4 vs 55.6, P = .03). The overall fusion rate was 68% in the CBM group (32/47 levels) and 78% in the rhBMP-2 group (36/46) (P = .35). Only preoperative hypertension was predictive of radiographic nonunion (odds ratio = 3.5, P = .05). There were 3 smokers in the CBM group and 4 smokers in the BMP group, and 1 in each group experienced radiographic pseudarthrosis. A total of 4 patients, 3 in the CBM group and 1 in the BMP group (P = .61), required revision for symptomatic pseudarthrosis. All of these patients had a single-level index procedure.
CONCLUSIONS: There were no differences in radiographic fusion and rate of revision surgery in patients who underwent MI-TLIF with either rhBMP-2 or CBM as fusion adjuncts. LEVEL OF EVIDENCE: 3. CLINICAL RELEVANCE: Both rhBMP-2 and CBMs can be used as effective fusion adjuncts without any clear advantage of one over the other.

Entities:  

Keywords:  TLIF; bone morphogenetic protein; cellularized bone matrix; lumbar spine fusion; minimally invasive transforaminal lumbar interbody fusion; rhBMP-2; stem cells

Year:  2019        PMID: 30805286      PMCID: PMC6383451          DOI: 10.14444/6007

Source DB:  PubMed          Journal:  Int J Spine Surg        ISSN: 2211-4599


  28 in total

1.  Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones.

Authors:  E Kon; A Muraglia; A Corsi; P Bianco; M Marcacci; I Martin; A Boyde; I Ruspantini; P Chistolini; M Rocca; R Giardino; R Cancedda; R Quarto
Journal:  J Biomed Mater Res       Date:  2000-03-05

Review 2.  Transforaminal lumbar interbody fusion.

Authors:  Alan Moskowitz
Journal:  Orthop Clin North Am       Date:  2002-04       Impact factor: 2.472

Review 3.  CT evaluation of lumbar interbody fusion: current concepts.

Authors:  Alan L Williams; Matthew F Gornet; J Kenneth Burkus
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

4.  Comparative study of PILF and TLIF treatment in adult degenerative spondylolisthesis.

Authors:  Deng-lu Yan; Fu-xing Pei; Jian Li; Cheng-long Soo
Journal:  Eur Spine J       Date:  2008-08-07       Impact factor: 3.134

5.  Pseudarthrosis in long adult spinal deformity instrumentation and fusion to the sacrum: prevalence and risk factor analysis of 144 cases.

Authors:  Yongjung J Kim; Keith H Bridwell; Lawrence G Lenke; Seungchul Rhim; Gene Cheh
Journal:  Spine (Phila Pa 1976)       Date:  2006-09-15       Impact factor: 3.468

6.  Cantilever TLIF with structural allograft and RhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome.

Authors:  Neel Anand; John F Hamilton; Brian Perri; Hamid Miraliakbar; Theodore Goldstein
Journal:  Spine (Phila Pa 1976)       Date:  2006-09-15       Impact factor: 3.468

7.  Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results.

Authors:  James D Schwender; Langston T Holly; David P Rouben; Kevin T Foley
Journal:  J Spinal Disord Tech       Date:  2005-02

8.  Comparison of plain radiographs with CT scan to evaluate interbody fusion following the use of titanium interbody cages and transpedicular instrumentation.

Authors:  Rajesh R Shah; Saeed Mohammed; Asif Saifuddin; Benjamin A Taylor
Journal:  Eur Spine J       Date:  2003-05-07       Impact factor: 3.134

9.  Clinical and radiographic comparison of mini-open transforaminal lumbar interbody fusion with open transforaminal lumbar interbody fusion in 42 patients with long-term follow-up.

Authors:  Sanjay S Dhall; Michael Y Wang; Praveen V Mummaneni
Journal:  J Neurosurg Spine       Date:  2008-12

10.  Effects of age and comorbidities on complication rates and adverse outcomes after lumbar laminectomy in elderly patients.

Authors:  Gordon Li; Chirag G Patil; Shivanand P Lad; Chris Ho; Wendy Tian; Maxwell Boakye
Journal:  Spine (Phila Pa 1976)       Date:  2008-05-15       Impact factor: 3.468

View more
  2 in total

1.  A Prospective, Multi-Center, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of the Synthetic Bone Graft Material DBM Gel with rhBMP-2 versus DBM Gel Used during the TLIF Procedure in Patients with Lumbar Disc Disease.

Authors:  Seung-Jae Hyun; Seung Hwan Yoon; Joo Han Kim; Jae Keun Oh; Chang-Hyun Lee; Jun Jae Shin; Jiin Kang; Yoon Ha
Journal:  J Korean Neurosurg Soc       Date:  2021-04-29

2.  Do preoperative clinical and radiographic characteristics impact patient outcomes following one-level minimally invasive transforaminal lumbar interbody fusion based upon presenting symptoms?

Authors:  Kyle W Morse; Ram K Alluri; Avani S Vaishnav; Hikari Urakawa; Jung Kee Mok; Sohrab S Virk; Evan D Sheha; Sheeraz A Qureshi
Journal:  Spine J       Date:  2021-10-23       Impact factor: 4.297

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.